AstraZeneca throws Redx a lifeline — in exchange for a preclinical fibrosis drug — with a promise of $17M in quick cash plus milestones
It’s not often that a deal with $17 million in near-term cash inspires a stock market rally. But for troubled UK biotech Redx, that kind …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
